18-Jun-2008 -
In-PharmaTechnologist.com presents a digest of recent developments in the world of pharmaceutical ingredients, with news involving Evonik, BASF, Qiqihar No. 2 Pharmaceutical Co and Shengtai Pharmaceutical.
30-Apr-2008 -
India's Dr Reddy's Laboratories has just announced the signing of a definitive agreement to buy the US pharmaceutical contract manufacturing business of chemicals giant BASF.
10-Apr-2008 -
Actavis has purchased a 90 per cent stake in Zhejiang Chiral Medicine Chemicals (CMC), a Hangzhou, China-based active pharmaceutical ingredients (API) maker.
03-Apr-2008 -
Three of India´s large pharmaceutical manufacturers, Dr Reddy's, Ranbaxy Laboratories and Shilpa Medicare have just announced new merger and acquisition (M&A) deals.
11-Jun-2007 -
A new technique could result in better nutritional and safety profiles for the coming generation of genetically modified organisms (GMOs), Spanish scientists have reported.
21-Feb-2007 -
Pharmaceutical services group Almac Sciences has teamed up with enzyme catalyst firm BioCatalytics on process development and manufacture of chiral intermediates and active pharmaceutical ingredients (APIs).
19-Feb-2007 -
Excelsyn and SAFC Both announced improvements to their UK contract manufacturing operations at this year's pharma services and specialty chemicals trade show, InformexUSA, in San Francisco.
16-Feb-2007 -
A round up of recent product releases from across the industry.
18-Dec-2006 -
Solvay has contracted Novasep to provide synthesis of two active pharmaceutical ingredients, following Novasep's decision to combine synthesis and processing expertise.
21-Nov-2006 -
Sigma-Aldrich (SAFC) will soon offer new solid-form research capabilities at its US high-potency active pharmaceutical ingredients (API) facility in Madison, Wisconsin.
30-Oct-2006 -
The global contract manufacturing market is expected to exceed $26bn (€20bn) by 2011, according to new market research.
12-Oct-2006 -
In its ambition to become one of the top three global players in custom manufacturing, the UK subsidiary of drug-maker Nicholas Piramal (NPIL) has created a new "innovation unit" in Europe.